



THE UNIVERSITY *of* EDINBURGH

## Edinburgh Research Explorer

### Antibiotic treatment and associated prolonged prothrombin time

**Citation for published version:**

Williams, KJ, Bax, RP, Brown, H & Machin, SJ 1991, 'Antibiotic treatment and associated prolonged prothrombin time', *Journal of Clinical Pathology*, vol. 44, no. 9, pp. 738-41.

**Link:**

[Link to publication record in Edinburgh Research Explorer](#)

**Document Version:**

Publisher's PDF, also known as Version of record

**Published In:**

Journal of Clinical Pathology

**General rights**

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

**Take down policy**

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [openaccess@ed.ac.uk](mailto:openaccess@ed.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.



# Antibiotic treatment and associated prolonged prothrombin time

K J Williams, R P Bax, H Brown, S J Machin

## Abstract

**The incidence and type of pathology causing a prolonged prothrombin time and clinical bleeding episodes were assessed in a multicentre study of 1109 patients receiving cefotetan, a N-methylthiotetrazole (NMTT), or equivalent antibiotics. There was no significant difference in the incidence of a prolonged prothrombin time (9.9% with cefotetan, 8.0% with comparable antibiotics) of clinical bleeding episodes. However, prothrombin time increases of greater than 12 seconds were significantly ( $p = 0.002$ ) greater with cefotetan (3.8%) than with comparators (0.8%). In both antibiotic groups increases in prothrombin time were more likely following surgery and in patients who were older, with a high platelet count, low albumin, or higher urea and creatinine concentrations. All antibiotic treatment can be associated with prolonged prothrombin times and new agents should always be assessed in a large multicentre study before the practical, clinical importance of haemostatic defects can be defined.**

There are numerous causes of acquired defects of the haemostatic mechanism, usually associated with multisystem disease, or drug treatment, which are responsible for, or precipitate, clinical bleeding episodes.<sup>1</sup>

When such events occur, or are expected, a series of simple laboratory screening tests, which are easy to perform and give reliable results quickly, are routinely undertaken.<sup>2</sup> The one stage prothrombin time is an essential test in all haemostatic screening procedures and increases of five seconds or more above the control range, in our experience, are particularly associated with clinical bleeding events. For many years antibiotic treatment has been implicated in various changes in the normal haemostatic process and precipitating bleeding.<sup>3,4</sup> Recently hypoprothrombinaemia and a prolonged prothrombin time have been specifically reported in association with several antibiotics, particularly cephamandole, moxalactam, and cefoperazone.<sup>5-7</sup> N-methylthiotetrazole (NMTT) containing antibiotics, such as moxalactam and NMTT alone, inhibit the vitamin K dependent carboxylation of glutamic acid residues in liver cells.<sup>8</sup>

Most clinical reports have emphasised, however, that a malnourished or debilitated

condition with relative vitamin K deficiency is also present before pathological increases in the prothrombin time and bleeding events occur.<sup>9,10</sup> With the background of multisystem disease and concurrent drug treatment it is difficult to implicate a single antibiotic in a specific haemostatic defect such as a prolonged prothrombin time. To do this, the effects of sepsis, surgery, and any underlying medical condition such as renal or liver failure would have to be separated from those of the antibiotic itself on prolonging the prothrombin time. Because of these problems there have been very few controlled studies of prolonged clotting times associated with specific antibiotic regimens.<sup>11</sup> Conflicting evidence has been published about the ability of relatively new NMTT containing antibiotics such as cefotetan to affect the prothrombin time and cause clinically important bleeding.<sup>12-14</sup>

Adverse reports are usually from one or two isolated cases which are often not corroborated by independent review. The importance of this problem has been highlighted by the regulatory licensing authorities insisting that prothrombin time data are now submitted when clinical trials with cephalosporin antibiotics are being designed and that reports are filed with all new antibiotics. This report evaluates how an open, random, comparative multicentre study was designed to investigate the incidence and degree of prothrombin time increases in patients being treated with intravenous cefotetan, which has the NMTT side chain, or comparator antibiotics, which do not, and the contribution of any associated risk factors.

## Methods

A total of 1109 patients in 19 centres throughout Europe and South Africa were randomly chosen to receive either cefotetan ( $n = 555$ ) or comparator antibiotic(s) ( $n = 554$ ), none of which contained the N-methylthiotetrazole (NMTT) side chain. The comparators were those given as standard practice in each centre and these included cefotaxime ( $n = 250$ ), benzyl penicillin or ampicillin/metronidazole and gentamicin ( $n = 218$ ), cefoxitin plus metronidazole ( $n = 12$ ), cefoxitin ( $n = 45$ ) and cephadrine plus metronidazole ( $n = 29$ ).

Children and pregnant women were excluded from the study and so were patients with known allergy to cephalosporins or to the alternative comparative treatment. Patients receiving other investigational or concurrent

ICI Pharmaceuticals,  
Mersey, Alderley  
Park, Macclesfield,  
Cheshire SK10 4TG

K J Williams

R P Bax

H Brown

Department of  
Haematology,  
Middlesex Hospital,  
London

S J Machin

Correspondence to:

K J Williams

Accepted for publication  
25 April 1991

Table 1 Demographic details of study population

	Group taking cefotetan (CTT)	Group taking comparators
Number of patients	555	554
Sex		
Males	248	249
Females	307	303
Mean age (years)	54	54
Age range (years)	14-89	12-93
Site of primary infection		
Intra-abdominal	243	235
Urinary tract	117	110
Respiratory tract	61	73
Soft tissue	54	54
Obstetric/gynaecological	64	62
Other	16	20

antimicrobial drugs were excluded. The demographic data are summarised in table 1.

All patients gave their informed consent for inclusion in the study and the study protocol was reviewed by the local ethical committees. A record form specifically designed for the study recorded data on factors which were potentially likely to affect prothrombin time. These included the history of antibiotics and operations in the preceding month. Any abnormal blood loss in this pretreatment period was recorded along with details of the event, possible cause, intensity, actions and outcome. During this period and the trial, details of the administration of blood or blood products, vitamin K, warfarin, heparin, parenteral nutrition, non-steroidal anti-inflammatory agents, steroids, aspirin or other relevant drugs were recorded.

If vitamin K was administered during the study it was recorded whether this was part of routine hospital practice, due to the finding of an abnormal prothrombin time on admission, or to an increase during the study period. In all cases the date of first administration of vitamin K was also noted. Details of all abnormal blood loss of whatever cause continued to be recorded during antibiotic treatment and immediately after treatment. In addition to a routine biochemical profile, full blood count, platelet count and differential, the one stage prothrombin time and normal control time were recorded in seconds. Such tests were performed immediately before treatment, during and at the conclusion of treatment, and at follow up, about 10 days after completion of treatment.

As the prothrombin times were measured in 16 different laboratories using different types of thromboplastin, the normal range varied between 11 and 16 seconds. Prolongation of the prothrombin time was defined as a five second increase outside the upper limit of the normal

Table 3 Range of significant increases in PT (percentages are of evaluable patients)

Range of significant increase	Treatment	
	Cefotetan N (%)	Comparators N (%)
No significant increase	454 (90.0)	461 (92.0)
5-12 seconds	31 (6.2)	36 (7.2)
> 12 seconds*	19 (3.8)	4 (0.8)
Total	504 (100.0)	501 (100.0)

\*Significantly different ( $p = 0.002$ ).

range, representing a significant change using European thromboplastins. In many of the patients with initially abnormal prothrombin times or with changes during treatment, a daily prothrombin time was recorded. Details of operations performed during treatment were recorded as well as a full history of all concurrent drugs, especially those known to affect the prothrombin time such as heparin, warfarin, and aspirin. The doses of both cefotetan or comparators were chosen to reflect the severity and site of the infection.

$\chi^2$  tests were carried out to test whether there was a significant association between treatment and incidence of a prothrombin time increase of over five seconds and with bleeding events during the study. The means of the prothrombin time increase for each treatment group were compared using a  $t$  test, because the mean of any distribution approaches normality as the number of observations becomes larger.

The  $t$  test was also used to detect differences in prothrombin time increases in the subgroups with surgery either during or before treatment, those with an already raised prothrombin time (more than five seconds), bleeding events before treatment and those receiving steroids, parenteral nutrition, or heparin.

For the multifactorial risk analysis, laboratory values were converted to the same units when necessary. Extreme outliers were found in some of the initial parameters at trial entry and these were incorporated into equations at the top of a defined clinically "sensible" range. In rare cases when a value was missing, a mean value was inserted. This leads to a smaller loss of variability than would have occurred if the patient was omitted, as happens in logistic regression.

## Results

The general condition of the patients and the severity of the major infection were similar in the two groups. A total of 883 (79.6%) had not received any antibiotics in the four weeks

Table 2 Incidence of prothrombin time changes of over five seconds

	Number of evaluable patients		Number with a prolongation of > 5 s		Percentage with > 5 seconds change	
	CTT	Comparators	CTT	Comparators	CTT	Comparators
All patients	504	501	50	40	9.9 (3.7-16.1)	8.0 (2.5-13.5)
Patients with initial PT prolonged	79	105	11	9	13.9 (7.2-23.6)	8.6 (4.0-15.7)

Figures in parentheses are 95% confidence intervals.

Table 4 Individual variables significantly associated with prothrombin time increase

Risk factor	PT increase < 5 s	PT increase 5–12 s	PT increase > 12 s
Operation during antibiotic course			
Yes	339 (85.2%)	41 (10.3%)	18 (4.5%)
No	569 (94.8%)	24 (4.0%)	7 (1.2%)
Age (years)	Mean (SD) 53.7 (21.7)	58.4 (22.7)	68.1 (20.2)
Platelets $\times 10^9/l$	Mean (SD) 304 (131)	328 (158)	320 (94)
Albumin g/l	Mean (SD) 39.1 (11.9)	34.8 (10.9)	32.5 (7.9)
Urea mmol/l	Mean (SD) 6.2 (3.8)	7.5 (5.4)	13.4 (10.4)
Creatinine $\mu\text{mol/l}$	Mean (SD) 99 (42)	106 (50)	166 (71)

Factors significantly associated with a prothrombin change greater than 5 seconds calculated for all 1005 assessable cases by performing a least squares regression.

Age ( $p = 0.0011$ )

Platelets ( $p = 0.0462$ )

Albumin ( $p = 0.0007$ )

Urea ( $p = 0.0001$ )

Creatinine ( $p = 0.0001$ )

No other clinical biochemical or haematological variables were significantly associated with a prothrombin time increase.

immediately before the study. Only 226 (20.4%) had received other antibiotics in the four weeks immediately before this study.

Of the 1109 patients randomly selected to receive either cefotetan (CTT) or comparator antibiotics, six were withdrawn from the analysis as they received warfarin with profound effects on prothrombin time. From the 1109 patients initially selected, 1005 had two or more prothrombin times performed. Of these, 9.5% had two measurements, 26.6% had three, 56.2% had four and 7.8% had five or more (the mean was 3.9).

The incidence of changes in the prothrombin time of over five seconds for all of the patients is shown in table 2. This also shows the subgroup of patients with an abnormally prolonged prothrombin time before treatment who developed further increases of over five seconds during treatment. The incidence of increased prothrombin time was not significantly different between the two groups. When the patients who developed an increase of prothrombin time of over 12 seconds are analysed, however, this is significantly higher in the group taking cefotetan ( $p = 0.002$ ) (table 3).

Out of the total of 1109 patients, vitamin K was only added to 77 patients—45 patients in the cefotetan group and 32 in the comparator group. Of the 77 additions, 27 were as a result of normal practice or an abnormal prothrombin time before antibiotics were started. In the remaining 50 cases vitamin K was added as a result of a rise of prothrombin time (30 taking cefotetan, 20 taking comparators) during treatment and resulted in a return to normal prothrombin time, and yet some with larger rises still had no vitamin K added.

An analysis of all of the patient characteris-

tics and laboratory data available showed that six clinical and laboratory variables were significantly related to the development of a prolonged prothrombin time (table 4).

The incidence of clinical bleeding events related to antibiotic use and prothrombin time changes are summarised in table 5. There was no difference between the incidence of bleeding events and treatment group, but bleeding was more common in patients with prolonged prothrombin times.

## Discussion

Although dose ranging studies on standard haemostasis tests in healthy volunteers are important in determining the safety profile during the development of all new antibiotics, they can give rise to a sense of false security. Indeed, several volunteer studies showed no increases in prothrombin time with moxalactam.<sup>15 16</sup> Only when the antibiotic is tested in large multicentre trials and patients with varying multisystem disease are given the drug can the potential effects on the prothrombin time be assessed properly. Most clinical trials include too few patients to assess uncommon events. This large multicentre study showed no significant difference in the number of subjects who developed a prolonged prothrombin time between those who received cefotetan alone (9.9%) or comparator antibiotics (8.0%) despite including 1109 patients. Only when those patients with increases of 12 seconds or more (3.8% with cefotetan and 0.8% with comparator antibiotics) were analysed was a significant difference between the groups found ( $p = 0.002$ ). There was no difference in clinical bleeding episodes between the two antibiotic treatment groups. The study, however, was able to show that in both treatment groups increases of prothrombin time were more likely to occur if the patients had an operation, were older, had a high initial platelet count, a lower serum albumin concentration, or higher urea and creatinine concentrations.

Regardless of the precise biochemical mechanism, malnutrition and vitamin K deficiency are more common in older patients with low serum albumin concentrations, and are likely to be acutely accentuated during gastrointestinal surgery when little oral nutrients are received in the first few pre-operative days.<sup>17</sup> Indeed, these theories have been proved in a small group of elderly post-operative patients receiving cefotetan with clinical features of malnutrition and low serum vitamin K<sub>1</sub> concentrations.<sup>18</sup>

Table 5 Clinical bleeding events

	Number of patients evaluable		Number of bleeds (during or at follow up)		Percentage of patients with bleeds	
	CTT	Comparators	CTT	Comparators	CTT	Comparators
No significant increase in PT	454	461	31	26	6.8 (1.7–1.9)	5.6 (0.4–10.6)
Increase > 5 seconds	50	40	6	4	12 (5–24)	10 (3–24)
All patients	504	501	37	30	7.3 (2.0–12.6)	6.0 (0.9–11.1)

Note: All bleeds are included irrespective of cause, and 95% confidence limits are given in parentheses.

Renal impairment, as well as affecting the elimination of antibiotic, may predispose to variable coagulation factor deficiencies, hepatic cell dysfunction, and uraemic enteritis, all of which can contribute to a prolonged prothrombin time.<sup>19</sup> Studies of the newer agents, especially the cephamycins, moxalactam, and cefotetan, have commonly included such compromised patients. We have shown, however, that all antibiotics, especially when given to patients in the above high risk categories, may coincidentally be associated with a prolonged prothrombin time, predisposing in some cases to clinical bleeding events. Prothrombin time alone is a poor indicator of vitamin K state and it may be appropriate to administer vitamin K to patients with the defined risk factors. In patients without these risks the NMTT containing antibiotic, cefotetan, did not cause more rises of prothrombin time than alternative antibiotics. Single case reports of antibiotic associated hypoprotebinaemia, which have been repeatedly reported, must now be judged against similar control groups receiving comparative antibiotic treatment. Only when such data are available can the true incidence and clinical importance of such events be judged. The results provided in this paper should provide guidance regarding the types of patients in the high risk categories.

We acknowledge the participation of the following people:  
From England: S Scott, S Karran, P Billings, D J Leaper, J Alexander Williams and M R B Keighley.  
From Germany: Drs R Hautmann, M Pfeiffer, H Hessler, K Lossnitzer, H K Horsch, N Lang and U Lochmueller.  
From South Africa: Dr M Marivate.  
From Italy: Professor Rondanelli.

- 1 Machin SJ. Acquired disorders of haemostasis. In: Hoffbrand AV, Lewis SM, eds. *Postgraduate haematology*. Oxford: Heinemann, 1989:655-71.
- 2 Machin SJ, Mackie IJ. *Laboratory haematology*. Edinburgh: Churchill Livingstone, 1989.
- 3 Ham JM. Hypoprotebinaemia in patients undergoing prolonged intensive care. *Med J Aust* 1971;2:716-18.
- 4 Brown CH, Natelson EA, Bradshaw MW. The haemostatic defect produced by carbenicillin. *N Engl J Med* 1974; 291:265-70.
- 5 Hooper CA, Haney BB, Stone HH. Gastrointestinal bleeding due to vitamin K deficiency in patients on parenteral cefamandole. *Lancet* 1980;i:39-40.
- 6 Pakter RL, Russell TR, Mielke CH, West D. Coagulopathy associated with the use of moxalactam. *JAMA* 1982; 248:1100-5.
- 7 Weitekamp MR, Caputo GM, Al-Mondhiry HAB, Aber RC. The effects of latamoxef, cefotaxime and ceftoperazime in platelet functions and coagulation in normal volunteers. *J Antimicrob Chemother* 1985;16:95-101.
- 8 Lipsky JJ. Mechanisms of the inhibition of the gamma-carboxylation of glutamic acid by N-methylthiotetrazole-containing antibiotics. *Proc Natl Acad Sci USA* 1984; 81:2893-7.
- 9 Bechtold H, Andrassy K, Jahnchen E, et al. Evidence for impaired hepatic vitamin K<sub>1</sub> metabolism in patients treated with N-methyl-thiotetrazole cephalosporins. *Thromb Haemostas* 1984;51:358-61.
- 10 Mackie IJ, Walshe K, Cohen H, et al. The effects of a NMTT-cephalosporin on haemostasis in patients with reduced serum vitamin K<sub>1</sub> levels. *J Clin Pathol* 1986; 39:1245-9.
- 11 Baxter JG, Marble DA, Whitfield LR, Wels PB, Walczak P, Schentag JJ. Clinical risk factors for prolonged PT/PTT in abdominal sepsis patients treated with moxalactam or tobramycin plus clindamycin. *Ann Surg* 1985;201:96-102.
- 12 Cohen H, Mackie IJ, Walshe K, et al. The effects of cefotetan disodium on haemostasis. *J Hosp Infect* 1987;10:51-7.
- 13 Holt J. Hypoprotebinaemia and bleeding diathesis associated with cefotetan therapy in surgical patients. *Arch Surg* 1988;123:523.
- 14 Smith KS, Quintiliani R, Nightingale CH. Cefotetan associated coagulopathies. *Arch Surg* 1989;124:388.
- 15 Bang NU, Tessler SS, Heidenreich RO, Marks CO, Mattler LE. Effects of moxalactam on blood coagulation and platelet function. *Rev Infect Dis* 1982;4:S546-54.
- 16 Bowcock S, Mackie IJ, Mo D, Mouldsdaie M, Billings P, Machin SJ. Effects of various doses of latamoxef on haemostasis. *J Hosp Infect* 1986;8:193-9.
- 17 Karran SJ, Alberti KGM. *Practical nutritional support*. London: Pitman Medical, 1980.
- 18 Cohen H, Scott SD, Mackie IJ, et al. The development of hypoprotebinaemia following antibiotic therapy in malnourished patients with low serum vitamin K<sub>1</sub> levels. *Br J Haematol* 1988;68:63-6.
- 19 Remuzzi G. Bleeding in renal failure. *Lancet* 1988;i:1205-8.